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Abstract
Background: Patients infected with HIV have an increased risk for accelerated atherosclerosis. Elevated levels of
osteoprotegerin, an inflammatory cytokine receptor, have been associated with a high incidence of cardiovascular
disease (including peripheral arterial disease, or PAD), acute coronary syndrome, and cardiovascular mortality. The
objective of this study was to determine whether PAD is prevalent in an HIV-infected population, and to identify
an association with HIV-specific and traditional cardiovascular risk factors, as well as levels of osteoprotegerin.
Methods: One hundred and two patients infected with HIV were recruited in a cross-sectional study. To identify
the prevalence of PAD, ankle-brachial indices (ABIs) were measured. Four standard ABI categories were utilized:
≤ 0.90 (definite PAD); 0.91-0.99 (borderline); 1.00-1.30 (normal); and >1.30 (high). Medical history and laboratory
measurements were obtained to determine possible risk factors associated with PAD in HIV-infected patients.
Results: The prevalence of PAD (ABI ≤ 0.90) in a young HIV-infected population (mean age: 48 years) was 11%.
Traditional cardiovascular risk factors, including advanced age and previous cardiovascular history, as well as
elevated C-reactive protein levels, were associated with PAD. Compared with patients with normal ABIs, patients
with high ABIs had significantly elevated levels of osteoprotegerin [1428.9 (713.1) pg/ml vs. 3088.6 (3565.9) pg/ml,
respectively, p = 0.03].
Conclusions: There is a high prevalence of PAD in young HIV-infected patients. A number of traditional
cardiovascular risk factors and increased osteoprotegerin concentrations are associated with abnormal ABIs. Thus,
early screening and aggressive medical management for PAD may be warranted in HIV-infected patients.
Background
HIV infection is an epidemic affecting an estimated 33
million people worldwide, with approximately 40,000
new cases reported each year in the United States [1].
There is evidence of accelerated atherosclerosis among
young patients infected with HIV [2]. Three recent
epidemiologic studies have reported an increased
prevalence of peripheral arterial disease (PAD) in HIV-
infected patients [3-5]. However, there is a paucity of
clinical data on the predictive risk factors and biologic
markers associated with PAD in HIV-infected patients.
Potential hypotheses for accelerated atherosclerosis in
HIV-infected patients include metabolic derangements
and direct effects of protease inhibitors (PIs), as well as
a primary impact of the HIV infection resulting in vas-
culopathy and vascular inflammation [2,6-8]. Recently,
PI use was found to be associated with PAD in HIV-
infected patients [9].
Peripheral arterial disease affects approximately 8 to
12 million people in the US and is an eminently treata-
ble disease [10]. Individuals with PAD have a seven- to
10-fold increased risk of cardiovascular ischemic events
and a short-term mortality that is increased at least
three fold compared with individuals without PAD at a
similar age [11]. The diagnosis of PAD has traditionally
been identified by detecting an ankle-brachial index
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demonstrated that low ABIs (<1.10) and elevated ABIs
(>1.40), which were previously considered normal, are
associated with an increase in all-cause and cardiovascu-
lar mortality [12].
Atherosclerosis has been well described as an inflam-
matory process [13]. Osteoprotegerin (OPG), a member
of the tumor necrosis factor receptor family, inhibits
receptor activator of nuclear factor-Bl i g a n d( R A N K L )
[14]. OPG has been implicated in bone remodelling, as
well as in atherosclerotic progression, vascular calcifica-
tion and vascular inflammation [15-18]. Moreover, ele-
vated levels of OPG have correlated with the onset of
cardiovascular events and an increased severity of PAD
[19,20].
The objective of this study was to evaluate the preva-
lence of, and risk factors associated with PAD in an
urban, HIV-infected population. The identification and
validation of non-invasive and surrogate markers of vas-
cular inflammation, such as OPG, in HIV-infected
patients may have a beneficial impact on early detection
and treatment for those with PAD.
Methods
Study population
Men and women 18 years of age or older with docu-
mented HIV infection were recruited from the Jack
Martin Fund Clinic, a New York State designated AIDS
center, located at the Mount Sinai Medical Center in
New York, New York. The clinic provides primary and
subspecialty care to approximately 1800 HIV-infected
patients. The ethnic make up of the clinic reflects a het-
erogeneous population within urban New York: 45% are
women, 45% are Hispanic, 44% are African American,
and less than 1% are Asian. Inclusion criteria included
HIV infection as documented by enzyme immunoassay
and confirmed by western blot analysis or a detectable
plasma HIV-1 RNA at any time prior to study entry.
This study was approved by the Institutional Review
Board of the Mount Sinai School of Medicine. All parti-
cipants provided written informed consent. Since this
study was intended to identify PAD secondary to ather-
osclerosis, exclusion criteria included the diagnosis of
vascular disease of non-atherosclerotic origin, such as
vasculitis (i.e. giant cell arteritis, Takayasu’sd i s e a s e ,
Buerger’sd i s e a s e ) .T h e r ew a sn oe x c l u s i o nb a s e do n
gender, socio-economic, racial or ethnic backgrounds.
Study design
This was a cross-sectional study. Subjects were recruited
from December 2005 to May 2006 by investigators with
the intention of enrolling patients on consecutive clinic
days to include patients cared for by all clinic providers.
This recruitment strategy was adopted to limit selection
bias. After informed consent was obtained, patients were
interviewed for demographic information, including gen-
der, ethnicity and birth date.
A limited physical exam was then performed to mea-
sure blood pressure (BP), pulse, height, weight and waist
circumference. Body mass index (BMI) was calculated
by dividing the weight in kilograms by the square of the
height in meters. In addition, medical charts were
obtained and reviewed for each patient recruited into
the study.
Cardiovascular risk factor evaluation
The presence of diabetes mellitus was determined by
self-report, chart documentation, or the use of diabetic
medication. The diagnosis of dyslipidemia was deter-
mined by self-report, clinical record, or the use of lipid-
lowering agents. In addition, patients were identified as
dyslipidemic if any of the lipid profiles from their medi-
cal record met National Cholesterol Education Panel
(NCEP) criteria [21]. Fasting glucose or lipid profiles
were not obtained as part of the protocol. Hypertension
was defined by self-report, chart documentation, or use
of anti-hypertensive medications.
A diagnosis of metabolic syndrome was determined by
identifying three of the following five criteria, as defined
by the NCEP: central obesity as measured by waist cir-
cumference; high BP; glucose intolerance; high triglycer-
ide levels; and low high density lipoprotein (HDL)
cholesterol concentration [21]. Patients were questioned
on previous and current smoking use.
A positive family history was defined as any first-
degree relative with a history of cardiovascular events in
a male under 55 years and female under 65 years. His-
tory of cardiovascular and cerebrovascular diseases was
obtained by self-report and/or chart review. History of
cardiovascular disease, including documented history of
coronary artery disease, was based on a history of stable
or unstable angina, myocardial infarction, percutaneous
coronary intervention, or coronary artery bypass graft
surgery. History of cerebrovascular disease was defined
as a history of transient ischemic attack, ischemic or
hemorrhagic stroke. The diagnosis of PAD was based on
a history of abnormal ABIs, percutaneous peripheral
arterial intervention, and peripheral arterial bypass
surgery.
HIV risk evaluation
Patients were interviewed regarding their previous and
current HIV medical history. Based on this interview
and medical chart review, the duration of HIV infection
was determined. The duration of protease inhibitor use
was obtained and recorded as total months. Current
CD4 count and viral load were determined by reviewing
the most recent laboratory results.
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The ankle-brachial index was measured by three study
participants (JJJ, AIS, DAA) who were trained by the
accredited vascular diagnostic laboratory at the Mount
Sinai Medical Center according to standardized labora-
tory procedures. Patients were placed in a supine posi-
tion following a five-minute rest period. While the
patient was supine, a BP cuff (Tycos, Welch Allyn, Ska-
neateles Falls, NY) was placed just above the elbow. An
8 mHz continuous wave hand-held Doppler transducer
probe (Nicolet Vascular, Madison, WI) was positioned
over the brachial artery. The BP cuff was then inflated
until the pulse signal was obliterated and inflation con-
tinued another 20 mmHg. After slowly releasing the cuff
pressure, the first audible tone was recorded as the bra-
chial systolic BP. This was repeated for both arms and
the highest brachial pressure was used for the ABI
calculation.
After both brachial artery blood pressures were
obtained, the BP cuff was placed approximately five cen-
timeters above the medial malleolus on each lower
extremity. The Doppler probe was positioned over the
posterior tibial (PT) arteries. The BP cuff was then
inflated until the pulse signal was obliterated and infla-
tion continued another 20 mmHg. After slowly releasing
the cuff pressure, the first audible tone was recorded as
the ankle systolic BP. This procedure was then repeated
on the opposite ankle for the PT systolic pressures, as
well as both arms above the elbow for brachial systolic
pressures.
For this study, only PT pressures were used to deter-
mine ABIs. The PT-only ABI method was chosen since
numerous large PAD epidemiological studies, including
National Health and Nutrition Examination Survey
(NHANES), used this technique [22-26]. The dorsalis
pedis pressure was used when the PT systolic pressure
was inaudible. The recorded ankle pressure was divided
by the highest brachial artery systolic pressures of either
arm.
The lower ABI of either limb was used to categorize
the patients into four designated ABI categories. The
ABI categories defined in this study include definite
PAD (ABI ≤ 0.90), borderline ABI (ABI = 0.91-0.99),
normal ABI (ABI = 1.00-1.30), and high ABI (ABI >
1.30). The four ABI categories used in this study were
similar to those previously described to not only diag-
nose PAD, but also to identify patients that may be at
increased risk for cardiovascular events [27].
Blood analysis
Complete blood count, basic chemistry panel and lipid
profiles were recorded from the patient’s most recent
laboratory test results. Plasma samples were analyzed for
inflammatory markers, including OPG, C-reactive
protein (CRP), interleukin-1b (IL-1b), and interleukin-6
(IL-6). The IMMAGE 800 assay (Beckman Coulter, Full-
erton, CA, USA), using a polyclonal anti-C-reactive pro-
tein antibody coated to latex particles, was used to
measure CRP concentrations. The IMMAGE CRPH is
based on the highly sensitive Near Infrared Particle
Immunoassay rate methodology (Beckman Coulter, Full-
erton, CA, USA). IL-1b, IL-6, and OPG were all assayed
using a quantitative sandwich immunoassay technique
(R&D Systems, Inc., Minneapolis, MN, USA). Antibodies
to IL-1b,I L - 6w e r eE. coli-derived and antibodies to
OPG were derived from a murine myeloma cell line
(R&D Systems, Inc., Minneapolis, MN, USA).
Statistical analysis
Associations between continuous variables and ABI
were tested using general linear models, after first trans-
forming to approximate normality, where necessary.
Logarithmic transformations were used for: glucose and
OPG; square root transformations for CD4, and both PI
and HIV durations; and reciprocal transformations for
viral load. Associations between binary variables and
ABI were tested using logistic regression models. All
models included contrasts to obtain statistics that com-
pare each other group to normal ABI (the reference
group). All associations were tested before and after
adjustment for potential confounding factors: age, sex,
BMI, smoking, diabetes mellitus, total cholesterol, HDL,
low density lipoprotein, triglycerides, CRP, cardiovascu-
lar disease, family cardiac history, duration of HIV and
duration of PI use. For all analyses, a p value < 0.05 was
considered statistically significant.
Results
Prevalence of PAD
The average age of the study population was 48.4 years
old. The prevalence of PAD (ABI ≤ 0.90) in this rela-
tively young HIV-infected population was 11%. Only
56% of the cohort had ABI measurements that were
considered normal (ABI 1.00-1.30). Of the remaining
study population, 18% had borderline ABIs (0.91-0.99),
while 15% had high ABIs (ABI >1.30) (Table S1, Addi-
tional file 1).
Risk factors for PAD associated with HIV infection
Potential HIV-specific risk factors, including duration of
protease inhibitor use, HIV exposure duration, CD4
count and viral load, were evaluated. However, none of
these risk factors were found to be independently pre-
dictive of abnormal ABIs in this cohort.
Cardiovascular risk factors associated with PAD
Despite the high prevalence of PAD identified by this
study, the majority of patients did not have traditional
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ham risk criteria: dyslipidemia (23%), hypertension
(28%), diabetes (12%), family cardiac history (23%), and
metabolic syndrome (25%) [28]. However, advanced age
significantly correlated with definite PAD compared to
normal ABIs [mean: 54.2 (12.8) years vs. 47.3 (8.0)
years, respectively; p = 0.02]. In addition, previously
documented cardiovascular disease was significantly
associated with PAD (p = 0.0005). Although 75% of the
cohort had a smoking history, smoking was not an inde-
pendent risk factor for PAD in this study.
Biomarkers for PAD
To assess for an association between inflammatory bio-
markers for PAD in HIV-infected participants, CRP, IL-
1b, IL-6, and OPG levels were measured. Elevated CRP
levels were significantly associated with definite PAD.
Concentrations of OPG were significantly elevated in
patients with high ABIs compared with patients with
normal ABIs [mean: 3088.6 (3565.9) pg/ml vs. 1428.9
(713.1) pg/ml, respectively; p = 0.03]. Levels of IL-1b,
and IL-6 did not significantly differ across ABI groups
(Table S1, Additional file 1).
Discussion
The salient observations from this study are that in this
relatively young, urban, HIV-infected cohort (1) there is
an 11% prevalence of PAD; (2) many HIV-infected indi-
viduals have abnormal ABIs, a known marker of
increased risk for cardiovascular events and mortality;
and (3) elevated OPG levels are associated with high
ABIs.
Based on large cross-sectional studies that used the
same ABI technique as in our study, the prevalence of
PAD (defined as ABI <0.90) was 12.4% in the Cardiovas-
cular Health Study, 19.1% in the Rotterdam Study,
18.0% in the Edinburgh Study, and 3.0% in the Athero-
sclerosis Risk in Communities study [22-25]. Interest-
ingly, the mean age of the aforementioned studies was
71.7-75.7 years, 69.0-71.7 years, 65.6-67.7 years, and
53.0-55.0 years, respectively [22-25]. The mean age of
the present study cohort was 48.4 years. Despite being a
significantly younger mean age, our cohort had an 11%
prevalence of PAD. In the National Health and Nutri-
tion Examination Survey (NHANES), the prevalence of
PAD in patients aged 40 to 49 years was only 0.6-1.1%
[26]. Thus, HIV-infected patients at similar ages to our
cohort may have an increased risk of PAD compared
with patients without HIV.
In addition to identifying patients with definite PAD
(ABI ≤ 0.90), the remainder of the cohort were classified
into three other ABI categories, defined as borderline
(ABI = 0.91-0.99), normal (ABI = 1.00-1.30) and high
(ABI >1.30). It has been well documented that patients
with ABIs <0.90 are two times more likely to have cardi-
ovascular events than patients with normal ABIs [25,29].
However, borderline ABIs (0.91-0.99), that previously
were considered normal, have now been associated with
mortality or cardiovascular disease morbidity of approxi-
mately 15% at six years [22]. Based on the Strong Heart
Study, patients with borderline ABIs (0.90-0.99, n = 195)
had approximately 30% increased risk for all-cause mor-
tality and approximately 10% increased risk for cardio-
vascular mortality [12]. In our HIV-infected cohort, the
prevalence of patients with ABIs = 0.91-0.99 was 18%.
This is especially important given that by Framingham
risk criteria, the majority of the patients in this study
would be classified as low risk (<10%) for cardiovascular
events and therefore would not have been screened
according to current American College of Cardiology/
American Heart Association (ACC/AHA) PAD practice
guidelines [28,30].
Recently, elevated ABIs, that previously were consid-
ered normal, have been associated with a significant risk
for cardiovascular mortality [12]. The Multi-Ethnic
Study of Atherosclerosis (MESA) found that men with
ABIs ≥ 1.30 had significantly elevated coronary calcium
scores compared with men with normal ABIs [27].
Interestingly, the mean age of the MESA cohort was
63.4 years, yet the prevalence of ABIs ≥ 1.30 was only
5.7% [27].
In the present cohort, with a mean age of 48.4 years,
the prevalence of ABIs >1.30 was 15%. Recently, Sharma
et al reported the prevalence of elevated ABIs in HIV-
infected women to be 7.2% [3]. Similarly, the prevalence
of elevated ABIs in our cohort of HIV-infected women
was 5%. In contrast, 10% of the HIV-infected men had
elevated ABIs. By combining all of our patients with
low, borderline and high ABI results, approximately 44%
of our cohort had ABIs that put them at significant risk
for cardiovascular events and mortality.
PAD is strongly associated with traditional cardiovas-
cular risk factors, such as advanced age, gender, dyslipi-
demia, hypertension, diabetes and tobacco use [31]. In
this study, advanced age and previously documented
cardiovascular disease (i.e., coronary artery disease, myo-
cardial infarction and stroke) was significantly associated
with definite PAD. From the NHANES database, there
is almost a doubling in the prevalence of PAD in men
with each decade of life from 40 to 70 years [26].
The oldest subgroup in the present study had a mean
age of 54.2 years. Despite being the oldest subgroup in
this study, they are considerably younger than previously
studied cohorts [22-25]. The NHANES study also
reported that approximately 33% of patients with PAD
had previously documented cardiovascular disease [26].
In this present study, there was only a 13% incidence of
previous cardiovascular disease.
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esis [13]. In our study, we observed that elevated CRP
concentrations are associated with definite PAD in our
cohort. Similarly, the NHANES study found that after
adjusting for traditional cardiovascular disease risk fac-
tors, patients with highest quartile of CRP had a 2.1-fold
increased odds for PAD [32].
Osteoprotegerin, a member of the tumor necrosis fac-
tor receptor family, inhibits receptor activator of nuclear
factor-B ligand (RANKL) [14]. OPG has been identified
as a regulator of bone formation and resorption [15].
OPG is found not only in bone, but also in the blood
vasculature (endothelium and smooth muscle cells)
where it plays a role promoting advanced atherosclero-
sis, calcification, and inflammation [16-18]. Elevated
levels of OPG have been associated with an increased
incidence of cardiovascular disease (including PAD),
acute coronary syndrome, and cardiovascular mortality
[19,33].
Although inflammatory markers, such as CRP, IL-1b,
and IL-6, are associated with cardiovascular diseases,
OPG is a unique biomarker in that elevated levels have
independently correlated with progression of coronary
artery calcification [34]. From our HIV-infected cohort,
elevated OPG levels, rather than CRP, IL-1b,a n dI L - 6 ,
were found to be associated with high ABIs. This is the
first study to document a correlation between elevated
O P Gl e v e l sw i t hh i g hA B I si ne i t h e rH I V -o rn o n - H I V -
infected patients. Interestingly, a number of previous
studies have observed that HIV-infected patients have
increased OPG levels compared to matched, non-HIV-
infected patients [35,36].
A few important limitations of this study deserve con-
sideration. The sample size is relatively small compared
with other prevalence studies evaluating PAD in HIV-
uninfected individuals. It is possible that certain cardio-
vascular and HIV risk factors may have reached or failed
to reach statistical significance as predictors for PAD
due to the small sample size of our study. Also, we did
not include a control group of HIV-uninfected patients
to serve as a comparison group. We cannot infer on the
mortality risk of our cohort with abnormal ABIs based
on data from previous studies of HIV-uninfected
patients. Perhaps, a future study investigating the risk of
mortality in HIV-infected patients with abnormal ABIs
may be warranted.
Conclusions
In summary, HIV-infected patients have a high preva-
l e n c eo fP A D .M a n yp a t i e n t sw i t hH I Vh a v ea b n o r m a l
ABIs, thus placing them at an increased risk for cardio-
vascular events and mortality. A number of cardiovascu-
lar risk factors, as well as elevated concentrations of
OPG, correlated with abnormal ABIs in HIV-infected
patients. Given the high prevalence and significant clini-
cal consequences associated with abnormal ABIs and
elevated OPG levels, early cardiovascular screening and
aggressive medical management may be warranted in
HIV-infected patients.
Additional file 1: Table S1: Characteristics of 102 HIV-infected
patients at the Jack Martin Fund Clinic, Mount Sinai Medical Center,
New York, New York. Data are presented as mean (standard deviation)
for continuous variables and number (No., %) for binary variables. ABI =
ankle-brachial index. SD = standard deviation. HDL = high density
lipoprotein. LDL = low density lipoprotein. IL-1b = Interleukin-1b.
IL-6 = interleukin-6. CVD = cardiovascular disease.
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